{
    "organizations": [],
    "uuid": "52f79b3ad0fea4c14039fd6053c918cb4394c58c",
    "author": "",
    "url": "https://www.reuters.com/article/brief-myokardia-begins-dosing-in-phase-2/brief-myokardia-begins-dosing-in-phase-2-maverick-hcm-clinical-trial-of-mavacamten-idUSASC09UGI",
    "ord_in_thread": 0,
    "title": "BRIEF-MyoKardia Begins Dosing In Phase 2 MAVERICK-HCM Clinical Trial Of Mavacamten",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 2, 2018 / 12:54 PM / Updated 7 minutes ago BRIEF-MyoKardia Begins Dosing In Phase 2 MAVERICK-HCM Clinical Trial Of Mavacamten Reuters Staff \nApril 2 (Reuters) - MyoKardia Inc: * OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY PATIENTS",
    "published": "2018-04-02T15:51:00.000+03:00",
    "crawled": "2018-04-02T16:04:09.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "begin",
        "dosing",
        "phase",
        "clinical",
        "trial",
        "mavacamten",
        "reuters",
        "staff",
        "april",
        "reuters",
        "myokardia",
        "inc",
        "obstructive",
        "hypertrophic",
        "cardiomyopathy",
        "patient"
    ]
}